Trials and studies
Long-term (3-year) open-label extension study1
- Sullivan J, Scheffer IE, Lagae L, et al. Fenfluramine HCl (Fintepla®) provides longterm clinically meaningful reduction in seizure frequency: Analysis of an ongoing open-label extension study. Epilepsia. 2020;61(11):2396-2404.
- Scheffer E, Devinsky O, Perry S, et al. Efficacy and Tolerability of Adjunctive FINTEPLA (Fenfluramine HCl) in an Open-Label Extension Study of Dravet Syndrome Patients Treated for Up to 3 Years. Presented at: the Virtual American Epilepsy Society (AES) Annual Meeting; December 4-8, 2020.